Literature DB >> 1385536

ELISA for quantitation of L-selectin shed from leukocytes in vivo.

O Spertini1, B Schleiffenbaum, C White-Owen, P Ruiz, T F Tedder.   

Abstract

L-selectin is a cell surface receptor on granulocytes, lymphocytes and monocytes that is responsible for the initial attachment of leukocytes to endothelium. The extracellular domain of L-selectin is proteolytically shed from leukocytes following cellular activation in vitro. The shed form of L-selectin (SL-selectin) is functionally active and at high concentrations can inhibit leukocyte attachment to endothelium. Therefore, an ELISA was developed to quantitate the levels of SL-selectin in biological fluids, biopsy specimens and during recombinant protein production. This simple, quantitative sandwich ELISA uses two monoclonal antibodies directed against the extracellular domain of SL-selectin. The assay has a detection range of 5-1300 ng/ml, is precise and sensitive. The ability of this assay to detect SL-selectin in serum, plasma, and culture supernatant fluid was demonstrated and it was used to quantitate circulating SL-selectin in normal and patient sera. Patients with sepsis and HIV infection showed markedly elevated SL-selectin levels in serum. Thus, the ELISA should prove useful both for laboratory purposes as well as in the diagnostic evaluation of patients with inflammatory diseases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385536     DOI: 10.1016/0022-1759(92)90017-n

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  27 in total

1.  Differential up-regulation of circulating soluble selectins and endothelial adhesion molecules in Sicilian patients with Boutonneuse fever.

Authors:  G Vitale; S Mansueto; G Gambino; C Mocciaro; C La Russa; P Mansueto; M A Zambito; V Ferlazzo; C Barbera; M La Rosa; S Milano; E Cillari
Journal:  Clin Exp Immunol       Date:  1999-08       Impact factor: 4.330

2.  Elevated serum L-selectin levels and decreased L-selectin expression on CD8(+) lymphocytes in systemic sclerosis.

Authors:  Y Shimada; M Hasegawa; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

3.  Systemic neutrophil activation in acute preschool viral wheeze.

Authors:  A Oommen; R Patel; M Browning; J Grigg
Journal:  Arch Dis Child       Date:  2003-06       Impact factor: 3.791

Review 4.  Expanding role of circulating adhesion molecules in assessing prognosis and treatment response in human immunodeficiency virus infection.

Authors:  Nikolaos V Sipsas; Petros P Sfikakis
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

5.  Calcium-dependent oligonucleotide antagonists specific for L-selectin.

Authors:  D O'Connell; A Koenig; S Jennings; B Hicke; H L Han; T Fitzwater; Y F Chang; N Varki; D Parma; A Varki
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

6.  Levels of soluble Fc gammaRIII correlate with disease severity in sepsis.

Authors:  A C Muller Kobold; J G Zijlstra; H R Koene; M de Haas; C G Kallenberg; J W Tervaert
Journal:  Clin Exp Immunol       Date:  1998-11       Impact factor: 4.330

7.  There is no change in soluble leucocyte selectin concentrations in whole blood after 48 hours of storage at 4 °C.

Authors:  Melville Bradley
Journal:  Blood Transfus       Date:  2014-09-12       Impact factor: 3.443

8.  ADAM17 deficiency by mature neutrophils has differential effects on L-selectin shedding.

Authors:  Ying Li; Jennifer Brazzell; Amy Herrera; Bruce Walcheck
Journal:  Blood       Date:  2006-05-30       Impact factor: 22.113

9.  Neutrophil adhesion molecules in term and premature infants: normal or enhanced leucocyte integrins but defective L-selectin expression and shedding.

Authors:  N Rebuck; A Gibson; A Finn
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

10.  Altered L-selectin expression in lymphocytes and increased adhesion to endothelium in patients with diabetic retinopathy.

Authors:  J R MacKinnon; R M Knott; J V Forrester
Journal:  Br J Ophthalmol       Date:  2004-09       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.